TickerTalks
Browse all tickers →
TickerTalks›$CELC
CECELC

Celcuity Inc.

$CELC·$3.3B·Biotechnology·Healthcare
$60.30+0.7%YTD-39.5%1Y+20.5%
Price updated 10h ago·X counts updated 4d ago
CECELC
$CELCCelcuity Inc.
$60.30+0.67%92 posts1×
AI analysisFundamentalsVoices on X
Loading…

On X

Top X posts

The complete picture of $CELC on X — how loud the conversation is right now, how it has trended over the last two weeks, and which way the crowd is leaning.

92X posts · last 7 days
Sep 28Oct 11
Chatter Meter
1×
QuietNormal · 1×Loud

How loud $CELC's conversation on X is versus its own normal — 1× is typical, higher means busier. Right now it's about its usual level.

Neutral sentimentAI analysisGenerated by AI from underlying data5 posts analyzed · as of 2026-09-10

Small $CELC pool with mixed data — one honest post lists Celcuity calls that went to zero as a recent loss, and short-tracker data has $CELC among the most crowded oncology shorts alongside SMMT and NBTX. A CEO fireside chat with Citi is the only 'news' beat. No clear direction.

Read what X is saying about $CELC

  • Bullish vs bearish call — with the AI summary of the day's posts
  • Divergence flag when the top-engagement posts argue the other side
  • How loud the conversation is versus this ticker's own normal
Free, forever. No credit card.

AI verdictAI analysisGenerated by AI from underlying data

TickerTalks' own read on what's driving $CELC — fundamentals, momentum, or an event — and whether it agrees with the X crowd.

Hinges on a big eventWinding up for a moveAI verdict · as of 2026-10-02

Trading in a tight range and building pressure — a move looks likely soon, but the direction isn't clear yet.

Celcuity is a crowded oncology short alongside SMMT and NBTX — the Citi fireside is the only visible catalyst.

Celcuity is a clinical-stage oncology biotech — gedatolisib in HR+/HER2- breast cancer and other PI3K-pathway tumors. The business is pre-revenue and the stock is in a drawdown.

  • The business is pre-revenue: PS reads as zero, operating margin uninformative, PE -24.9 — standard clinical-stage biotech P&L where today's numbers are irrelevant.
  • 52-week range position is 33% with vol multiplier 3.11 — massive accumulation volume in the lower-mid range, which lines up with the thread's observation that CELC is among the most crowded oncology shorts.
  • The thread is honestly muted: one trader admitted CELC calls went to zero, short-tracker data shows CELC crowded alongside SMMT and NBTX, and the Citi fireside is the only operational anchor on the near-term calendar.

Nov 11 Q3 is the gate — any gedatolisib Phase 3 readout commentary plus visible cash runway extends the move. A clinical disappointment or dilutive raise and the stock stays range-bound at the lower levels.

What to watch: Nov 11 Q3 earnings and the gedatolisib Phase 3 readout timing. A clinical disappointment or dilutive raise before readout is the hard invalidator.

On the calendar: 2026-11-11 — Q3 earnings

Read the AI verdict on $CELC

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • Whether TickerTalks' read agrees with or diverges from the X crowd
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Clinical-stage oncology biotech developing molecularly targeted therapies for solid tumors based on cellular pathway analysis.

Industry overviewAI analysisGenerated by AI from underlying data

Where Biotechnology sits in its cycle right now — and what that implies for $CELC.

Biotechnology · Healthcare

No material change from last week — mRNA oncology platform remains the structural driver.

What this means for $CELC

Partial — Clinical-stage oncology biotech developing molecularly targeted therapies for solid tumors based on cellular pathway analysis.

Top industry ETF

$IBBiShares Biotechnology ETF
+17.9%YTD
+35.2%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
-24.9How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
-49.5%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
0.0%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
-4.0%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
0.0Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
-245%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
0.0%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
3.7Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q2 2026Aug 13, 2026$-1.44$-1.16-24.1%
Q1 2026May 14, 2026$-0.97$-1.04+6.7%
Q4 2025Mar 25, 2026$-0.97$-1.06+8.5%
Q3 2025Nov 12, 2025$-0.92$-1.02+9.8%
Next earningsWed, Nov 11·consensus EPS $-1.45

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q1 FY26$0———$-0.97$-55.3M
Q4 FY25$0———$-0.96$-36.5M
Q3 FY25$0———$-0.92$-44.9M
Q2 FY25$0———$-1.04$-36.3M

Forward consensus

5-year forecast · up to 7 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$22.2M$4.9M – $38.1M-$5.10-$5.32 – -$4.837
FY27$325.6M$176.3M – $516.7M-$2.35-$3.96 – $0.057
FY28$770.0M$438.9M – $1.3B$2.15-$0.16 – $6.577
FY29$1.3B$666.2M – $2.2B$6.53$2.45 – $12.923
FY30$1.8B$912.9M – $3.1B$9.81$3.67 – $19.405

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.1.7×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.13%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.-27.9%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.-41.4%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatLow float · 29.7M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today7.1% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β0.165-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

SellJul 14Baker Bros. Advisors LpFormer 10% owner3.1M sh$317.8MSellMay 4David DalveyDirector25.0K sh$3.5MSellMay 4Richard E BullerDirector9.0K sh$1.3M
+ 16 other (10 awards · 3 exempts · 3 gifts) in window

See when $CELC insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

3New insider — initial holdingsOct 53
8-KOfficer or director changeOct 28-K — Item 5.02: Officer or director change · Item 7.01: Press release / Reg FD
8-KPress release / Reg FDSep 308-K — Item 7.01: Press release / Reg FD · Item 8.01: Other event
AI summary

Celcuity Inc. (CELC) filed a Regulation FD disclosure (8-K Item 7.01) on 2026-09-30. Combined with other events items. The excerpt shows only the cover page; the actual disclosed material (typically investor presentation slides, a press release, or conference call transcript) is attached as an exhibit. Reg FD events can contain forward-looking statements or updated guidance material to investors.

8-KPress release / Reg FDAug 268-K — Item 7.01: Press release / Reg FD · Item 8.01: Other event
AI summary

Celcuity Inc. submitted a supplemental New Drug Application (sNDA) to the FDA for REVTORPYK (gedatolisib), seeking approval to treat HR+/HER2- locally advanced or metastatic breast cancer patients with a PIK3CA mutation after progression on at least one line of endocrine therapy. This is a major regulatory milestone: the sNDA submission puts gedatolisib on a formal FDA review pathway for a substantial breast cancer patient population, potentially unlocking a broad new commercial indication for Celcuity.

SC 13D/AActivist amendmentJul 16SC 13D/A
AI summary

Baker Bros. Advisors LP and related entities (Julian C. Baker, Felix J. Baker, and Baker Bros. Advisors (GP) LLC) filed Amendment No. 2 to their SC 13D on Celcuity Inc. (CELC), disclosing 4,877,963 shares representing 9.99% of the class. Baker Bros. is classified as an investment advisor (IA/PN); no activist intent is stated in the excerpt. Significant position update by a prominent healthcare-focused investment manager at just under the 10% threshold.

8-K/APress release / Reg FD (amended)Jul 158-K/A — Item 7.01: Press release / Reg FD · Item 8.01: Other event
AI summary

Celcuity (CELC) filed Amendment No. 1 to its 8-K originally dated July 15, 2026, to correct a missing slide in Exhibit 99.2 (investor presentation). The underlying event covered by the original filing was the FDA approval of REVTORPYK (gedatolisib) for the treatment of HR+/HER2- locally advanced or metastatic breast cancer in patients without a PIK3CA mutation who had received at least one prior endocrine therapy. No new substantive information was added beyond the corrected exhibit. This amendment ensures the investor presentation is complete.

8-KPress release / Reg FDJul 158-K — Item 7.01: Press release / Reg FD · Item 8.01: Other event
AI summary

Celcuity (CELC) announced on July 14, 2026, that the FDA approved REVTORPYK (gedatolisib) for the treatment of HR+/HER2- locally advanced or metastatic breast cancer in patients without a PIK3CA mutation following at least one prior endocrine-based therapy. The company expects a commercial launch in late Q3 2026 and plans to file a supplemental NDA (sNDA) in Q3 2026 targeting the PIK3CA-mutant breast cancer indication. Gedatolisib is a pan-PI3K/mTOR inhibitor. This approval establishes REVTORPYK in a defined patient population with an unmet need.

8-KAgreement terminatedJun 88-K — Item 1.01: Material agreement · Item 1.02: Agreement terminated · Item 2.03: Material debt obligation · Item 8.01: Other event
AI summary

Celcuity Inc. (CELC) disclosed a material definitive agreement under Item 1.01, reporting a merger or acquisition transaction involving growth company as defined in Rule. The deal is valued at approximately $557.0 million. Details of the transaction terms, consideration structure, and closing conditions are set forth in the full 8-K filing. Definitive merger agreements are among the most material events a public company can disclose, triggering regulatory review and shareholder vote requirements.

+ 15 other (4 8-Ks · 3 13Gs · 2 10-Qs · 2 earnings 8-Ks) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

New Strong Sell Stocks for October 14thzacks.com·2d agoCelcuity Announces Multiple Presentations At The European Society For Medical Oncology (ESMO) Congress 2026globenewswire.com·11d agoCelcuity Appoints David Gryska To Its Board Of Directorsglobenewswire.com·14d agoCelcuity (NASDAQ:CELC) Shares Gap Up – Time to Buy?defenseworld.net·14d agoWhy Celcuity Stock Was a Winner on Wednesdayfool.com·16d ago

More in Biotechnology

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$MRNA$ALEC$NWBO$DNA$NVAX$CAI$IBRX$RXRX
Voices on X · top 1 · last 7 days

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport